Find information on thousands of medical conditions and prescription drugs.

Fibrosis

Fibrosis is the formation or development of excess fibrous connective tissue in an organ or tissue as a reparative or reactive process, as opposed to formation of fibrous tissue as a normal constituent of an organ or tissue. more...

Home
Diseases
A
B
C
D
E
F
Fabry's disease
Facioscapulohumeral...
Factor V Leiden mutation
Factor VIII deficiency
Fallot tetralogy
Familial adenomatous...
Familial Mediterranean fever
Familial periodic paralysis
Familial polyposis
Fanconi syndrome
Fanconi's anemia
Farber's disease
Fascioliasis
Fatal familial insomnia
Fatty liver
Febrile seizure
Fibrodysplasia ossificans...
Fibromatosis
Fibrosarcoma
Fibrosis
Fibrous dysplasia
Filariasis
Fissured tongue
Fitz-Hugh-Curtis syndrome
Flesh eating bacteria
Fluorosis
Focal dystonia
Foix-Alajouanine syndrome
Follicular lymphoma
Fountain syndrome
Fragile X syndrome
Fraser syndrome
FRAXA syndrome
Friedreich's ataxia
Frontotemporal dementia
Fructose intolerance
Fructose-1,6-bisphosphatase...
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Diseases: -

  • cystic fibrosis of the pancreas and lungs
  • endomyocardial fibrosis, idiopathic myocardiopathy
  • cirrhosis is fibrosis of the liver
  • idiopathic pulmonary fibrosis of the lung
  • diffuse parenchymal lung disease
  • mediastinal fibrosis
  • progressive massive fibrosis, a complication of coal workers' pneumoconiosis
  • proliferative fibrosis, neoplastic fibrosis
  • tuberculosis (TB) can cause fibrosis of the lungs

Adjective - fibrotic

Read more at Wikipedia.org


[List your site here Free!]


Pulmonary fibrosis: is lung transplantation a valid and viable alternative to medical therapy?
From CHEST, 10/1/05 by Carlo Banfi

PURPOSE: Interstitial lung disease is a heterogeneous group of subacute or chronic illnesses, which may lead to respiratory failure and death in a large number of patients. Idiopathic pulmonary fibrosis is the most common form of such a diseases.

METHODS: From January 1991 to April 2005, 243 patients affected by pulmonary fibrosis were referred to lung transplantation waiting list: 110 (45%) died, 90 (37%) underwent lung transplantation, 22 (9%) are still enrolled and 21 (9%) were suspended from the list. Actuarial survival of patients on waiting list (medical therapy) is summarized on table 1.

RESULTS: 90 patients affected by pulmonary fibrosis underwent 94 transplantations, with 4 patients undergoing retransplantation. There were 80 (89%) single lung transplants with 45 twinning procedures, 9 (10%) double lung transplants and 1 (1%) heart-lung transplant. Cardiopulmonary by-pass was used in 11% of patients (mean time 163 [+ or -] 84 min), total ischemic time was 242 [+ or -] 86 minutes. Median of mechanical ventilation was 2 days; median ICU and hospital stay was 5 and 17 days, respectively. Postoperative mean FEV1 increased from a preoperative level of 46% of the predicted value to 69% at 1 month and 74% at 12 months. Actuarial survival after lung transplant is summarized on table 2. The incidence of postoperative complications was 1,02 patient. Airway complications occurred in 20 patients (23%). Comparison of survival rates between transplanted patients and patients on waiting list are highly significant (p<0,000001).

CONCLUSION: Lung transplantation is an excellent but, by now, the only one therapeutic option for patients affected by end-stage pulmonary fibrosis. Currently medical treatment of pulmonary fibrosis with single or combined immunosuppressive therapy has not been found to improve survival of these patients. Lung transplantation is also effective in improving respiratory function and returning many patients to active life.

CLINICAL IMPLICATIONS: The high mortality of patients affected by pulmonary fibrosis on waiting list and the lack of donors for lung transplant impose the search for new therapeutic modalities in pulmonary fibrosis.

DISCLOSURE: Carlo Banfi, None.

[GRAPHICS OMITTED]

Carlo Banfi MD * Andrea M. D'Armini MD Mauro Rinaldi MD Carlo Pellegrini MD Mario Vigano MD Division of Cardiac Surgery IRCCS Policlinico S Matteo, Pavia, Italy

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Fibrosis
Home Contact Resources Exchange Links ebay